Literature DB >> 46958

Gallbladder disease in hyperlipoproteinaemia.

K Einarsson, K Hellström, M Kallner.   

Abstract

The occurrence of gallbladder disease (G.B.D.) (cholelithiasis, cholecystitis, cholecystectomy) was examined in patients consecutively admitted beccause of hyperlipoproteinaemia types IIa and IV. Altogether 37 of the 52 patients with the type IIa pattern were women, whereas 56 of the 75 subjects with hyperlipoproteinaemia type IV were men. The overall incidence of G.B.D. in the group with the type IIa was 13 per cent in the males and 22 per cent in the females; the corresponding figures in type IV were 41 per cent and 68 per cent, respectively. The findings in the major age-group (40-59 years) were compared with those from three necropsy series covering subjects of the same age. The incidence of G.B.D. was then found to be normal in type IIa but abnormally high in type IV. Patients with and without G.B.D. did not differ with regard to body-weight or glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46958     DOI: 10.1016/s0140-6736(75)92831-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Cholelithiasis in subjects with hypercalcaemia and primary hyperparathyroidism detected in a health screening.

Authors:  T Christensson; K Einarsson
Journal:  Gut       Date:  1977-07       Impact factor: 23.059

2.  Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

Authors:  I J A M Jonkers; A H M Smelt; M Ledeboer; M E Hollum; I Biemond; F Kuipers; F Stellaard; R Boverhof; A E Meinders; C H B W Lamers; A A M Masclee
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Clofibrate therapy and gallstone induction.

Authors:  M C Bateson; D Maclean; P E Ross; I A Bouchier
Journal:  Am J Dig Dis       Date:  1978-07

4.  Gallbladder disease and hyperlipoproteinemia.

Authors:  M C Bateson
Journal:  Dig Dis Sci       Date:  1980-04       Impact factor: 3.199

Review 5.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

6.  Plasma lipids and insulin in gall stone disease: a case-control study.

Authors:  R K Scragg; G D Calvert; J R Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-01

7.  Resistance to chenodeoxycholic acid (CDCA) treatment in obese patients with gall stones.

Authors:  J H Iser; P N Maton; G M Murphy; R H Dowling
Journal:  Br Med J       Date:  1978-06-10

8.  Familial hyperlipoproteinemia and gallstones.

Authors:  A Singh
Journal:  Can Med Assoc J       Date:  1975-10-18       Impact factor: 8.262

9.  [Relation between serum lipoprotein metabolism and biliary lipid metabolism].

Authors:  O Leiss; K von Bergmann
Journal:  Klin Wochenschr       Date:  1983-06-15

10.  Serum lipids and lipoproteins in patients with gallstone (relationship between serum lipids and types of stones in roentgenograms and sectional views).

Authors:  G Kajiyama; M Fujiyama; K Takata; A Miyoshi
Journal:  Gastroenterol Jpn       Date:  1981-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.